Stanley Lapidus insider trades: Lucid Diagnostics (LUCD) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Stanley reports to the SEC
Open-market buys and sales
6 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 26, 2023 | LUCD | ↓ Sell | 29,947 | $1.45 | $43K | Direct | Sep 27, 2023 (1d) |
| Sep 21, 2023 | LUCD | ↓ Sell | 3,917 | $1.45 | $6K | Direct | Sep 22, 2023 (1d) |
| Sep 20, 2022 | LUCD | ↓ Sell | 33,864 | $1.70 | $58K | Direct | Sep 22, 2022 (2d) |
| Jun 11, 2019 | TTOO | ↓ Sell | 9,000 | $1.44 | $13K | Direct | Jun 13, 2019 (2d) |
| Nov 6, 2018 | TTOO | ↓ Sell | 6,048 | $5.29 | $32K | Direct | Nov 8, 2018 (2d) |
| Jun 5, 2018 | TTOO | ↓ Sell | 6,000 | $8.87 | $53K | Direct | Jun 5, 2018 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other LUCD insiders
Open-market trades in the last 12 months
About Stanley Lapidus's insider trades
Stanley Lapidus is a director at Lucid Diagnostics (LUCD). Since Jun 5, 2018, Stanley has reported no open-market purchases and 6 sales worth $205K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (9 filings), option exercises (4 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every LUCD insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.